Nurix Therapeutics (NRIX) Other financing activities (2019 - 2026)

Nurix Therapeutics (NRIX) has reported Other financing activities for 8 consecutive years, with $1.2 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Other financing activities rose 20250.0% year-over-year to $1.2 million; the TTM figure through May 2026 stood at $3.6 million (up 230.09% YoY), while the FY2025 annual figure was $2.2 million, up 4.55% from the prior year.
• Other financing activities rose to $1.2 million in Q2 2026 per NRIX's latest filing, from $375000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $2.3 million in Q3 2024 and bottomed at -$93.0 million in Q4 2022.
• Historically, Other financing activities has averaged -$6.0 million across 5 years, with a median of $644500.0 in 2024.
• Annual changes were most pronounced in 2022 — Other financing activities tumbled 7874.87% — and 2026, when it surged 20250.0%.
• Nurix Therapeutics' Other financing activities stood at -$93.0 million in 2022, then jumped by 102.34% to $2.2 million in 2023, then slumped by 167.74% to -$1.5 million in 2024, then surged by 235.82% to $2.0 million in 2025, then tumbled by 39.01% to $1.2 million in 2026.
• Business Quant data shows NRIX's Other financing activities at $1.2 million in Q2 2026, $375000.0 in Q1 2026, and $2.0 million in Q3 2025.